IP Library Granted Patent US 9,623,117
Granted Patent B2
US 9,623,117 · App. 13/435,688 · Granted Apr 18, 2017

Method for selective targeting and entry of bacterial toxins to cells

Inventors: Edwin Raymond Chapman (Madison, WI); Felix Leejia Yeh (San Francisco, CA)
Assignee: Wisconsin Alumni Research Foundation
A61K47/48484A61K47/48561
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,623,117
App. No.
13/435,688
Granted
Apr 18, 2017
Kind
B2
Abstract

The present invention provides methods and reagents for directing the selective targeting and entry of bacterial toxins to mammalian cells. Methods include the step of contacting a cell with a bacterial toxin or toxic bioactive fragment thereof associated with an antibody or ligand that is specific to a target on the cell, wherein the antibody or ligand selectively binds the target on the cell and the bacterial toxin or fragment thereof is internalized and enters the cell. The invention further encompasses compositions and kits to carry out the methods.

Claims (10)

1. A method for selectively targeting a bacterial toxin to a cell, comprising contacting a cell with a toxic bioactive fragment of a bacterial toxin associated with an antibody or ligand that is specific to a target protein on the cell, wherein the toxic bioactive fragment is associated with the antibody or ligand by an avidin/biotin or streptavidin/biotin linkage, wherein the antibody is selected from the group consisting of a low density lipoprotein receptor antibody, a transferrin receptor antibody, and a vesicular dopamine transport antibody, wherein the toxic bioactive fragment is the enzymatic domain of the bacterial toxin and lacks a functional receptor binding domain; whereby the toxic bioactive fragment is internalized and enters the cell upon selective binding of the antibody or ligand to the target protein.

2. The method according to claim 1 , wherein the bacterial toxin is a clostridium neurotoxin.

3. The method according to claim 1 , wherein the bacterial toxin is selected from the group consisting of botulinum neurotoxin A (BoNT/A), botulinum neurotoxin B (BoNT/B), botulinum neurotoxin C (BoNT/C), botulinum neurotoxin D (BoNT/D), botulinum neurotoxin E (BoNT/E), botulinum neurotoxin F (BoNT/F), botulinum neurotoxin G (BoNT/G), tetanus neurotoxin (TeNT), Diphtheria toxin, and Pseudomonas exotoxin.

4. The method according to claim 1 , wherein the target protein is a plasma membrane protein or a protein located at a plasma membrane of the cell.

5. The method according to claim 1 , wherein the target protein is a receptor protein.

6. The method according to claim 1 , wherein the target protein is a protein located at a secretory vesicle of the cell.

7. The method according to claim 1 , wherein the target protein is a component of the cell's complement system and entry is mediated by said complement system.

8. The method according to claim 1 , wherein the cell is an immune cell, a neuronal cell, an exocrine gland cell, or an endocrine gland cell.

9. The method according to claim 1 , wherein the cell is a cancer or tumor cell.

10. The method according to claim 1 , wherein the cell is contained in a subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2012
From: CHAPMAN, EDWIN; YEH, FELIX
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 028240/0526 →
CONFIRMATORY LICENSE Recorded Apr 6, 2012
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028003/0192 →
Continuity (2)
Provisional Application 61471406 · Apr 4, 2011
Related Publication 20150283261A1 · Oct 8, 2015